Plain-English translation of NCT06330584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Anxiety research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing intranasal midazolam—a fast-acting medication delivered through the nose—to see if it can help calm acute anxiety in patients hospitalized for palliative (end-of-life) care. The study will compare three groups: patients receiving the medication at a standard dose, patients receiving double the standard dose, and patients receiving a placebo (fake treatment with no active ingredient). Researchers want to understand whether this treatment works, how safe it is, and how the body processes it.
Anxiety is common and distressing for patients in palliative care, but quick, effective treatments are limited. This medication has been used for anxiety relief, but researchers need to test it rigorously to confirm it works well in this specific patient population and to find the best dose.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the medication at a standard dose, double the standard dose, or a placebo spray—all delivered through your nose. Your anxiety levels will be measured right before you receive the spray and again 30 minutes later. The study team will also monitor your heart rate, oxygen levels, and sedation over the next 24 hours and track whether you need additional doses for anxiety. Some participants will also have blood samples taken at several time points to help researchers understand how the body processes the medication.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Switzerland